2017. ISPOR Latin America Conference – Secukinumab shows greater symptomatic improvement versus etanercept in psoriatic arthritis: Comparative effectiveness up to 24 weeks assessed by matching-adjusted indirect comparison

Mease P, Choy E, Thom H, Kalyvas C, Lopes N, Pricop L, Gandhi K, Jugl SM, Nash P. Secukinumab shows greater symptomatic improvement versus etanercept in psoriatic arthritis: Comparative effectiveness up to 24 weeks assessed by matching-adjusted indirect comparison. Value Health. 2017 Oct-Nov;20(9):A936. Presented at: ISPOR 6th Latin America Conference 2017; September 15-17, 2017; Sao Paulo, Brazil.